Skip to main content

Table 4 Relations between CYP2C19, CYP2D6, CYP3A5 and SULT1A1 genotypes and tamoxifen and its metabolites in postmenopausal women (n = 90)

From: Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

    Median concentration [q1 - q3] 1
Genotype (n)    tamoxifen 4OHtam 4OHNDtam NDtam NDDtam tamNox
CYP2C192 *2/*2 (4) 107 [79 - 137] 5.1 [3.3 - 5.2] 45.7 [41.3 - 54.7] 263 [156 - 404] 47.0 [39.0 - 67.4] 12.8 [10.3 - 31.8]
  *1/*2 (15) 107 [79 - 140] 5.8 [5.1 - 8.9] 61.2 [43.2 - 83.9] 233 [194 - 322] 44.8 [40.2 - 71.4] 9.7 [8.5 - 16.5]
  *1/*1 (35) 92 [79 - 118] 5.5 [4.6 - 6.8] 49.6 [44.7 - 61.6] 231 [190 - 357] 38.1 [26.7 - 46.4] 9.5 [7.4 - 12.7]
  Vt*17 (33) 95 [76 - 126] 6.1 [5.0 - 7.4] 53.3 [41.4 - 67.4] 229 [196 - 319] 37.8 [25.6 - 55.1] 9.1 [6.3 - 10.8]
  *17/*17 (3) 154 [31 - 157] 11.3 [3.0 - 17.2] 94.3 [34.0 - 184.8] 341 [142 - 438] 36.9 [15.7 - 79.0] 11.1 [3.5 - 11.7]
P3    0.371 0.240 0.652 0.600 0.022* 0.002**
CYP2D64 PM (6) 85 [58 - 125] 4.0 [3.1 - 5.5] 37.4 [31.8 - 48.2] 296 [179 - 444] 47.0 [22.8 - 55.9] 9.2 [6.1 - 21.0]
  IM (32) 87 [78 - 141] 5.9 [4.6 - 6.9] 50.5 [38.6 - 62.8] 243 [217 - 358] 38.2 [24.9 - 44.7] 9.4 [7.1 - 11.0]
  Wt/Wt (51) 99 [80 - 124] 6.1 [5.0 - 8.1] 55.5 [45.7 - 69.7] 223 [117 - 299] 40.4 [33.0 - 55.6] 9.8 [7.4 - 13.4]
  UM (1) 107 5.8 46.3 185 40.3 9.0
P    0.358 0.019* 0.009** 0.044* 0.413 0.958
CYP3A5 Vt/Vt (76) 96 [75 - 127] 5.6 [4.7 - 7.0] 49.9 [41.3 - 65.5] 228 [189 - 316] 38.4 [27.0 - 51.4] 9.4 [6.9 - 11.8]
  Wt/Vt (14) 102 [81 - 162] 6.8 [5.7 - 10.2] 54.6 [49.4 - 80.6] 297 [221 - 396] 45.7 [32.7 - 67.3] 12.0 [9.7 - 14.5]
P    0.203 0.074 0.154 0.075 0.052 0.044*
SULT1A1 Vt/Vt (14) 91 [68 - 138] 5.5 [4.1 - 7.5] 48.6 [40.4 - 60.7] 228 [185 - 353] 37.1 [23.4 - 49.8] 9.3 [6.9 - 11.8]
  Wt/Vt (32) 103 [90 - 141] 6.0 [5.1 - 7.3] 58.5 [46.2 - 75.3] 244 [201 - 361] 44.8 [37.9 - 57.6] 10.7 [8.7 - 15.2]
  Wt/Wt (44) 87 [80 - 105] 5.4 [4.6 - 8.9] 51.3 [40.8 - 73.5] 219 [183 - 294] 36.9 [25.7 - 49.4] 9.0 [6.8 - 10.1]
P    0.649 0.512 0.286 0.755 0.197 0.712
SULT1A1copy numbers 1 (3) 84 [80 - 168] 6.7 [6.1 - 8.9] 55.1 [49.0 - 85.0] 278 [217 - 364] 37.9 [24.2 - 60.4] 9.7 [6.9 - 10.6]
  2 (59) 92 [68 - 123] 5.6 [4.6 - 6.8] 50.5 [41.2 - 64.4] 227 [188 - 299] 38.4 [27.7 - 47.9] 9.4 [6.6 - 11.7]
  3 (21) 107 [87 - 162] 6.9 [5.2 - 9.8] 52.7 [46.6 - 80.2] 271 [198 - 395] 46.5 [33.0 - 59.2] 9.8 [8.3 - 13.8]
  4 (5) 103 [82 - 139] 5.1 [4.2 - 7.5] 58.6 [39.1 - 71.7] 223 [205 - 346] 38.1 [28.4 - 62.3] 12.7 [8.4 - 14.5]
  5 (2) 86 [51 - 122] 6.2 [4.1 - 8.4] 49.2 [32.4 - 66.1] 260 [150 - 371] 45.1 [23.1 - 67.2] 11.7 [5.6 - 17.7]
P4    0.352 0.863 0.719 0.475 0.370 0.280
  1. 1Median concentration [quartile 1 - quartile 3] values of tamoxifen and metabolites are given as ng/ml.
  2. 2*2/*2, encodes defective CYP2C19 activity; Vt*17, subjects heterozygous for the variant type allele CYP2C19*17 (*1/*17 and *2/*17); *17/*17, encodes ultra rapid CYP2C19 activity.
  3. 3P values were calculated by multivariate logistic regression model, *p < 0.05. Adjusted for CYP2C19, CYP2D6, CYP3A5, SULT1A1, SULT1A1 copy number, FSH and SHBG.
  4. 4PM, poor metabolizer; IM, wild type/variant type; Wt/Wt, wild type/wild type; UM, ultra rapid metabolizer.